Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch: Roivant Spins Out Arvelle, Licenses Epilepsy Candidate From SK Biopharma

Executive Summary

Already having launched several portfolio companies, Roivant goes a step further by spinning out CNS specialist Arvelle from Axovant. BI and IBM will incorporate blockchain technology in clinical trials, while AbbVie licenses multiple myeloma candidate from TeneoBio.

Advertisement

Related Content

AbCellera Finds Antibody Candidates Other Technologies Might Not
Glenmark Spins Out Innovation With New US Base
Korean Firms Join Hands To Pick Up Troubled US Cancer Vaccine Firm Argos
US Rights Deal Will Make Proleukin Clinigen's Biggest Product
Almirall Extends Dermatology Reach With Dermira Lebrikizumab Deal
New Option For Uncontrolled Epilepsy On Horizon As US Accepts Cenobamate NDA
Galapagos Targets Liver Fibrosis With Evotec Deal
Medicxi Links With Sosei Heptares For Orexin Agonist Vehicles
Glenmark, Yuhan Partner for Ryaltris, Eyes On US Trajectory

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC124683

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel